• PSS28 Economic Burden of Advanced Melanoma- Findings From A Large US Health Insurance Database

    Nov 1, 2011, 00:00

  • PMS76 Treatment Patterns Among Patients with Shoulder Osteoarthistis

    Nov 1, 2011, 00:00

  • PRM51 Nonparametric Regression Analysis Controls Cost Analysis in Data with Outliers

    Nov 1, 2011, 00:00

  • PIN100 Why Don't Health Practitioners Prescribe Rationally in Malaria? A qualitative Study from Pakistan

    Nov 1, 2011, 00:00

  • PMH72 The Impact of Once-Daily Extended-Release Quetiapine Fumarate (Quetiapine XR) on Length of Hospitalisation of Patients with Acute Bipolar Mania

    Nov 1, 2011, 00:00

  • PCN178 Reimbursement of Cancer Drugs in the UK- New Approach to End-of-Llife Treatments and the Technology Appraisal Programme of NICE

    Nov 1, 2011, 00:00

  • PMD37 Cost-Effectiveness of the Ex-Press Glaucoma Filtration Device in France

    Nov 1, 2011, 00:00

  • PIN31 Quantifying the Financial and Disease Burden Associated with Mother to Child Transmission of HIV in Uganda

    Nov 1, 2011, 00:00

  • PSY57 Waist Circumference and Body Mass Index Recording – A Thin Database Study

    Nov 1, 2011, 00:00

  • PCN152 Can Breast Cancer Risk Prediction Reduce the Risks of False Negative and False Positive Screening Mammograms?

    Nov 1, 2011, 00:00

  • PRS34 Cost-Effectiveness of Roflumilast (DAXAS®) in the Treatment Of Chronic Obstructive Pulmonary Disease (COPD) in Spain

    Nov 1, 2011, 00:00

  • PRS60 The Impact of Severe Poor-Controlled Asthma On Patients' Quality of Life Control Study

    Nov 1, 2011, 00:00

  • PGI23 Economic Impact of Medication Adherence and Persistence in the Treatment of Ulcerative Colitis in Canada- Analyses with the Ramq Database

    Nov 1, 2011, 00:00

  • PIN23 To Assess or Not To Assess- That is the Question! Budget, Ethical and Decisional Impact assessment in HIV- Lombardy Region's Molo Project

    Nov 1, 2011, 00:00

  • PCV5 Cost-Effectiveness and Budget Impact Analysis of Rivaroxaban in the Prevention of Thromboembolic Events in Patients Performing Hip and Knee Arthroplasty in Comparison with No Treatment Under the Brazilian Private Health Care System Per ...

    Nov 1, 2011, 00:00

  • PRM30 A Comparison of the Patientslikeme Quality of Life Questionnaire (PLMQOL) with the Rand SF-36

    Nov 1, 2011, 00:00

  • PHP30 Biosimilars in the European Market

    Nov 1, 2011, 00:00

  • PDB47 Understanding the Implications of Incorporating the UKPDS Glycaemic Legacy Effect Into Evaluating the Cost-Effectiveness of Type 2 Diabetes Therapies

    Nov 1, 2011, 00:00

  • PIH57 Pediatric Daycare in Belgium

    Nov 1, 2011, 00:00

  • PGI25 Chronic Hepatitis C (CHC) Related Flu-like Symptoms; Development of a Patient Report Outcome (PRO) Measure and Results from Pilot Efficacy Studies

    Nov 1, 2011, 00:00

  • PHP56 The Emergent Role of the Specialist Pharmacist as an Important Stakeholder in Market Access

    Nov 1, 2011, 00:00

  • PND33 Cost Minimization Analysis of Fingolimod Compared to Natalizumab in Patients with Relapse Remitting Multiple Sclerosis in the Netherlands

    Nov 1, 2011, 00:00

  • PMH76 Patterns and Determinants of Sickness Absence Among Users of Antidepressants in a Danish Working Population

    Nov 1, 2011, 00:00

  • PGI2 Cost-Effectiveness Analysis of the Use of Adalimumab for the Treatment of Crohn's Disease (CD) in Mexico

    Nov 1, 2011, 00:00

  • PSY44 Association of the Obesity and Weight-Loss Quality-of-Life Score With Patient Demographics and Measures of Obesity

    Nov 1, 2011, 00:00

  • PHP8 ATC Classification and Its Role in Pricing Policies

    Nov 1, 2011, 00:00

  • PCV142 A Review of the Primary Care Prescribing of Dabigatran Etexilate and Rivaroxaban in Ireland

    Nov 1, 2011, 00:00

  • PIN21 Clinico-Economic Evaluation of Treatment of Community-Acquired Pneumonia (CAP) Complicated by Sepsis with Moxifloxacin Compared to Ceftriaxone + Azithromycin

    Nov 1, 2011, 00:00

  • PCV148 Multiple Propensity Score Analysis to Estimate Treatment Effects in Patients with Heart Failure

    Nov 1, 2011, 00:00

  • PHP2 Relation Between Consumer Behaviour and Drug Safety Monitoring in France

    Nov 1, 2011, 00:00

  • PCN40 Health Care Resources Utilization and Costs in Metastatic Melanoma

    Nov 1, 2011, 00:00

  • PSS41 Impact on Quality of Patients With Active and Inactive Psoriasis in Spain

    Nov 1, 2011, 00:00

  • PSY7 Budget Impact Analysis of Bendamustine in the Treatment of Multiple Myeloma in Spain

    Nov 1, 2011, 00:00

  • PMS29 Abatacept or Infliximab for Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate- A Trial-Based and Real-Life Cost-Consequence Analysis

    Nov 1, 2011, 00:00

  • DA1 Artificial Neural Network Meta-Models in Cost-Effectiveness analysis of intensive Blood-Glucose Control- A Case Study Applied to the UK prospective Diabetes Study (UKPDS) Individual Patient outcome Simulation Model

    Nov 1, 2011, 00:00

  • PHP17 Mexico'S National and Institutional Essential Medicine Lists

    Nov 1, 2011, 00:00

  • PCN147 Health-Related Quality of Life in Head and Neck Cancer Patients - Comparison with General Population Norms

    Nov 1, 2011, 00:00

  • PCV6 Cost-Effectiveness and Budget Impact Analysis of Rivaroxaban in the Prevention of Thromboembolic Events in Patients Performing Hip and Knee Arthroplasty in Comparison With Enoxaparin Under the Brazilian Private Health Care System Persp ...

    Nov 1, 2011, 00:00

  • PCN69 Cost-Effectiveness Analysis of Rituximab Maintenance Treatment of Follicular Lymphoma in Patients Responding to First-Line Inmunochemotherapy Induction

    Nov 1, 2011, 00:00

  • PIH1 Comparison of Unintended Pregnancy Rates in Users of 84/7, 21/7, and 24/4 Oral Contraceptive Regimens

    Nov 1, 2011, 00:00

  • PSY3 Use Of A Discrete Event Simulation Model To Estimate Long Term Economic Outcomes Of Bariatric Surgery In Morbidly-Obese, Type-2 Diabetic Patients In Mexico

    Nov 1, 2011, 00:00

  • PIH46 Satisfaction with Prescription and Over-the-Counter Medications- Results from a Novel Patient Registry

    Nov 1, 2011, 00:00

  • PMS41 Assessing the Cost Effectiveness of Broadening Access to Alendronate for the Prevention of Osteoporotic Fracture in Australia

    Nov 1, 2011, 00:00

  • PIN96 Does Connecting Tobacco Cessation Intervention in Tuberculosis Care Improve Quality of Life Outcomes?

    Nov 1, 2011, 00:00

  • PHP93 Regional Differences among Methadone Maintenance Programs in Spain

    Nov 1, 2011, 00:00

  • PHP51 Pill Burden in South African Patients With Multiple Risk Factors for Metabolic Syndrome

    Nov 1, 2011, 00:00

  • PUK1 Belatacept Versus Tacrolimus- Results of an Indirect Analysis from a Systematic Review of Immunosuppressive Therapies for Kidney Transplant Recipients

    Nov 1, 2011, 00:00

  • PND45 Development and Validation of the Multiple Sclerosis Rating Scale-Revised (MSRS-R)

    Nov 1, 2011, 00:00

  • PCV73 Cost Effectiveness of Speech and Language Therapy Following Stroke

    Nov 1, 2011, 00:00

  • PMH32 Cost-Effectiveness of Agomelatine in the Treatment of Major Depressive Episodes in Thailand

    Nov 1, 2011, 00:00

  • PCN89 Public Health Impact of Quadrivalent HPV Types 6, 11, 16, 18 Vaccine in Sao Paulo, Brazil Using A Transmission Dynamic Model

    Nov 1, 2011, 00:00

  • PSY15 Striving for Affordable Treatments Within the Greek Environment- Do Epoetin Biosimilars Help?

    Nov 1, 2011, 00:00

  • PSS6 Epidemiology, Disease Burden, Symptomatology, Treatment Pattern, and Quality of Life in Macular Degeneration in Korea- Systematic Literature Review Based on Korean Evidence

    Nov 1, 2011, 00:00

  • PMD73 Comparisons of Anaphylactoid Reactions Associated With Different Gadolinium Products and Iodinated Contast Media Using the FDA's Adverse Event Reporting System

    Nov 1, 2011, 00:00

  • PIN91 Sensitivity of Pro's in Evaluating Adverse Events in People Receiving Influenza Vaccination

    Nov 1, 2011, 00:00

  • PHP48 Os Motivos Que Levam O JudiciÁrio A Determinar Que Os Planos De SaÚde ForneÇam MedicaÇÃo oral Em Oncologia

    Nov 1, 2011, 00:00

  • PDB45 Cost-Effectiveness of Transferring Type 2 Diabetic Patients from Neutral Protamine Hagedorn (NPH) to Detemir in Portugal Settings

    Nov 1, 2011, 00:00

  • PSS2 Prevalence, Demographics and Treatment Characteristics of Visual Impairment Due to Diabetic Macular Edema in A Representative Canadian Cohort

    Nov 1, 2011, 00:00

  • PUK10 Cost-Effectiveness Analysis of Solifenacin Versus Oxybutynin Immediate-Release in the Treatment of Patients with Overactive Bladder in the United Kingdom

    Nov 1, 2011, 00:00

  • PCN112 Cost-Utility of Treatment for Acute Lymphoblastic Leukemia (ALL) in Childhood

    Nov 1, 2011, 00:00

  • PHP162 Impact of AMNOG on Pharmaceutical Pricing Trends in Germany

    Nov 1, 2011, 00:00

  • PHP3 Patient Preferences Considering the Choice of Health Care Providers in Hungary – Results From Discrete Choice Experiment

    Nov 1, 2011, 00:00

  • PMH29 Cost Effectiveness of Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Turkey in Patients with Major Depressive Disorder (Mdd) Who Have Failed Previous Antidepressant Therapy

    Nov 1, 2011, 00:00

  • PMH82 Examining Variability in Depression Among Pre-Retirees- Innovative Analytic Methods Applied to Observational Data

    Nov 1, 2011, 00:00

  • PHP46 Market Uptake of Orphan Drugs – A European Analysis

    Nov 1, 2011, 00:00

  • PSY18 Resource Consumption Evaluation for Ketoprophene, Ketorolac, Parecoxib and Tenoxicam at Orthopedic Surgery Post-Operation in Brazilian Patients from Private Payers Perspective

    Nov 1, 2011, 00:00

  • PND66 Cross-Cultural Adaptation and Validation of the Brazilian Version of the Fatigue Severity Scale (FSS)

    Nov 1, 2011, 00:00

  • PCV19 Prescription of Angiotensin Converting Enzyme Inhibitors and Hypertension Control in Diabetic Hypertensive Patients

    Nov 1, 2011, 00:00

  • PHP4 Significant Decrease in the Hungarian Health Insurance Pharmaceutical Budget Between 2006-2009

    Nov 1, 2011, 00:00

  • NI4 The Association between Financial Impact and the likelihood of recommendation of Medicines for Use in England and Wales

    Nov 1, 2011, 00:00

  • PRM39 Identification of Diseases for EQ-5D Bolt-on Item Development- An Empirical Approach

    Nov 1, 2011, 00:00

  • PHP114 Performance Indicators of Intensive Care in Hungary

    Nov 1, 2011, 00:00

  • PCN87 The Cost Effectiveness of Cetuximab (Erbitux) in the Third Line Treatment of Metastatic Colorectal Cancer in the UK

    Nov 1, 2011, 00:00

  • PND48 Development of A Burden Questionnaire- Family Burden of Ichthyosis in Infants

    Nov 1, 2011, 00:00

  • PCV36 High Dose and Long-Term Safety of Systemic Corticosteroids in the Treatment of Polymylagia Rheumatica and Vasculitis- A Systematic Review

    Nov 1, 2011, 00:00

  • PHP38 Market Access for Pharmaceuticals in UK- Number and Speed of Drug Reviews to Improve After Introduction of Value Based Pricing

    Nov 1, 2011, 00:00

  • PIN13 Epidemiology of Staphylococcus Aureus Infections in Children- A Literature Review of the Last 10 Years

    Nov 1, 2011, 00:00

  • PCN23 Survival Analyses Adjusted for Crossover in Relapsed Multiple Myeloma- Results of the Apex Trial

    Nov 1, 2011, 00:00

  • PCN77 Cost-Effectiveness of Granulocyte Colony Stimulating Factor (G-CSF) in Primary (PP) and Secondary Prophylaxis (SP) of Febrile Neutropenia (FN) in Patients with Stages 2 and 3 Breast Cancer (BC) Undergoing Cytotoxic Chemotherapy in Fra ...

    Nov 1, 2011, 00:00

  • PMS70 Evaluation of Prescribed Pain Medications Prior to the Initiation of Duloxetine Therapy in a Commercially Insured Population

    Nov 1, 2011, 00:00

  • UT3 The Validity Of The EQ-5D, SF-6D, SF-36 and SF-12 In Mental Health Conditions- A Systematic Review

    Nov 1, 2011, 00:00

  • VA1 Evaluacion Rápida Del Impacto De La Introduccion De La Vacuna Contra El Rotavirus En Colombia

    Nov 1, 2011, 00:00

  • PCN24 Budget Impact Model for Rare Cancer Treatment- Case in Point Cutaneous T-Cell Lymphoma

    Nov 1, 2011, 00:00

  • PIN41 Cost-Benefit Analysis of Regional Procured Essential Medicines in the Southern African Development Community (SADC) with a Focus on Access to Antiretroviral Drugs

    Nov 1, 2011, 00:00

  • PRM6 Validating an Alternative Weighting Algorithm of the Charlson Comorbidity Index (CCI) for Risk Adjustment in Previously Hospitalized Patients

    Nov 1, 2011, 00:00

  • PRS42 Pharmacoeconomic Analysis of Methylprednisolone Aceponate for Treatment of Atopic Dermatitis and Eczema

    Nov 1, 2011, 00:00

  • PCN171 Underlying Causes for Sub-Optimal Utilisation of Cancer Drugs Funds in England

    Nov 1, 2011, 00:00

  • PRM66 Comparison of Reconciliation and Review Methodologies for the Translation of Patient Reported Outcome (PRO) Measures

    Nov 1, 2011, 00:00

  • PHP129 Societal Preferences for Health Technology Disinvestment Policy- Views of Scottish Taxpayers – A Qualitative Study

    Nov 1, 2011, 00:00

  • PGI33 Predictors of Direct Medical Costs of Crohn'S Disease and Ulcerative Colitis

    Nov 1, 2011, 00:00

  • PSU14 Complications and Costs Associated with Tubal Ligations

    Nov 1, 2011, 00:00

  • ISPOR 3rd Latin America conference disclosure information for reserch presentations

    Nov 1, 2011, 00:00

  • PSS21 Treatment Patterns, Costs and Quality of Life in Patients With Plaque Psoriasis in Denmark

    Nov 1, 2011, 00:00

  • PSY26 Cost Benefit Analysis of a Worksite Weight Management Program

    Nov 1, 2011, 00:00

  • PCV6 Comparison of Bleeding Rates between Statin and Statin-Free Patients on Warfarin- A Claims Database Approach

    Nov 1, 2011, 00:00

  • PMH7 Aasenapine Versus Other Antipsychotics in Bipolar I Disorder- Indirect Comparisons at Twelve Weeks

    Nov 1, 2011, 00:00

  • PND20 A Cost-of-Illness Analysis Of Amyotrophic Lateral Sclerosis In Greece

    Nov 1, 2011, 00:00

  • PRS8 Predicted Survival for North American Patients with Cystic Fibrosis Adjusted for Cohort Specific Covariates

    Nov 1, 2011, 00:00

  • PCN200 Using A Weibull Parametric Model for Failure-Time Data to Assess Progression-Free Survival as A Surrogate Endpoint for Overall Survival in A Trial of Patients with Metastatic Renal Cell Carcinoma

    Nov 1, 2011, 00:00

  • PIH40 Designing a Disease-Specific Patient Reported Outcome (PRO) for a Rare Disease- Assessing the Reliability, Validity, and Responsiveness of the Hunter Syndrome - Functional Outcomes for Clinical Understanding Scale (HS-Focus)

    Nov 1, 2011, 00:00

  • PIN37 The Cost of Managing Chronic Hepatitis C in Sweden - Medical Resource Utilisation in Different Stages of the Disease

    Nov 1, 2011, 00:00

  • PMH21 Economic Cost of Alcohol and Drug Abuse in Washington State, USA

    Nov 1, 2011, 00:00

  • PHP20 Economic Evaluation of Poison Control Centers- A Systematic Review

    Nov 1, 2011, 00:00

  • PSS35 Validation of the Eighteen Item Functional Assessment of Visual Tasks (Vistas-18) Using A New Lens Prescription Methodology

    Nov 1, 2011, 00:00

  • PIN12 Epidemiology, Outcomes, and Costs of Hospitalization Due to Pneumonia, Meningitis, and Septicemia in Canada from 2004 to 2010

    Nov 1, 2011, 00:00

  • PHP58 Towards Cost-Effectiveness Analysis of the Health and Wellbeing Benefits of Urban Green Spa A Mapping Review

    Nov 1, 2011, 00:00

  • PCN44 Cost-of-Illness Study of Human Papillomavirus Cancers in England

    Nov 1, 2011, 00:00

  • CV2 Cost-Effectiveness of Prasugrel Versus Clopidogrel in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention in the Private Sector in México

    Nov 1, 2011, 00:00

  • PHP1 Kenya'S Village Aging insensitivity to Aging Policies

    Nov 1, 2011, 00:00

  • PMD60 Development and Content Validity of the COPD Device Preference Questionnaire

    Nov 1, 2011, 00:00

  • PRM49 Evaluation of Bivariate Meta-analysis Methods to Synthesise Results of Several Studies with Two Correlated Endpoints

    Nov 1, 2011, 00:00

  • PSS24 Cost-Effectiveness of Ustekinumab vs Etanercept for Severe Psoriasis

    Nov 1, 2011, 00:00

  • PHP84 Assessing Productivity and Activity Impairment Due to Illness in Poland- Employees Versus Employers View

    Nov 1, 2011, 00:00

  • PHP15 Price Negotiations in Korean Pharmaceutical Benefit System- How Compatible with CEA?

    Nov 1, 2011, 00:00

  • PMH26 Direct Cost of Schizophrenia in Quebec, Canada- An Incidence-Based Microsimulation Monte-Carlo Markov Model

    Nov 1, 2011, 00:00

  • PRM14 Mondriaan- A Dutch 'Population' Laboratory

    Nov 1, 2011, 00:00

  • PMD43 An Evidence-Based Microsimulation Model for Chronic Graft versus Host Disease in Spain

    Nov 1, 2011, 00:00

  • PHP38 Health Technology Assessment Applied to Medical Devices in Latin America- What Must Be Assessed

    Nov 1, 2011, 00:00

  • PCV79 Economic Evaluation of Rosuvastatin Versus Atorvastatin, Simvastatin and Pravastatin in High Risk Patients Treated for Primary and Secondary Prevention of Cardiovascular Disease in Greece

    Nov 1, 2011, 00:00

  • PND40 A Study to Estimate Utility Values for Different Levels of Severity of Migraine Pain

    Nov 1, 2011, 00:00

  • PMH19 Cost of Relapse in Schizophrenia in Europe- The Constatre Study

    Nov 1, 2011, 00:00

  • PRM62 The Impact of Centre Selection on the Generalisability of Economic Evaluation Results from Multi-Centre Randomised Controlled Trials

    Nov 1, 2011, 00:00

  • PCN47 Clinical and Economic Burden of Breast Cancer in Japan- A Diagnosis Procedure Combination–Based Claims Database Survey

    Nov 1, 2011, 00:00

  • PCV138 Using a Population- Based, Budget- Constrained, Cost-Effectiveness Model to Assess the Health and Economic Impacts of Using Statins for Primary Prevention Based on the Jupiter Trial intended Use Population

    Nov 1, 2011, 00:00

  • PHP37 Regional Drug Evaluation in Spain- A Comparison Among Committees

    Nov 1, 2011, 00:00

  • AD1 Compliance Measurement Using Administrative Data From German Sickness Funds

    Nov 1, 2011, 00:00

  • PCV64 the Potential Clinical and Economic Outcomes of Pharmacogenetic-Oriented Warfarin Therapy in Russia

    Nov 1, 2011, 00:00

  • PCN6 Evaluacion Economica Del Dasatinib En El Tratamiento De La Leucemia Mieloide Cronica En Pacientes Resistentes Al Imatinib En Chile

    Nov 1, 2011, 00:00

  • PCV95 Economic Analysis of Interventions to Improve Control of Blood Pressure in Nigerian Hospitals

    Nov 1, 2011, 00:00

  • PHP70 Value Based Pricing (VBP)- Is This the Way Forward for the UK NHS?

    Nov 1, 2011, 00:00

  • PCV84 Resource Utilization and Costs for Candesartan in Heart Failure- Assessment of Reduction in Mortality and Morbidity (CHARM) Programme for the Austrian Setting

    Nov 1, 2011, 00:00

  • PCV45 Health Economic Evaluation of Ticagrelor in Patients with Acute Coronary Patients (ACS) Based on the Plato Study from A Spanish Health Care Perspective

    Nov 1, 2011, 00:00

  • PDB56 Development of a New Measure for Assessing Health Related Quality of Life (HRQOL) in Patients with Primary Hyperparathyroidism (PHPQoL)

    Nov 1, 2011, 00:00

  • PIH2 Addressing Childhood Obesity In Mexico- Savings On Health Care Expenditures From Regulating Food And Beverage Sales In Basic Education Schools

    Nov 1, 2011, 00:00

  • PCV76 A Cost-Effectiveness Analysis of Clopidogrel in Patients with Non Stable Acute Coronary Syndrome in Greece

    Nov 1, 2011, 00:00

  • PRS51 The Development of the Early Morning Symptoms of COPD Instrument (EMSCI)

    Nov 1, 2011, 00:00

  • PCV145 Predicting Healthcare Expenditures and Utilization in Patients with Dyslipidemia Using the updated Charlson Comorbidity Index (CCI) and Prior Expenditures

    Nov 1, 2011, 00:00

  • PND6 Outcomes of Antiepileptic Drugs Uses at Doses Above the Recommended Range Among Children with Structural-Metabolic Epilepsy in Malaysia

    Nov 1, 2011, 00:00

  • UT1 Combining DCE and TTO Into A Single Value Function

    Nov 1, 2011, 00:00

  • PSS32 Impact of Dry Eye on Everyday Life (Ideel) - Symptom Bother- Estimating Cut-off Scores for Dry Eye Severity Groups

    Nov 1, 2011, 00:00

  • PCV9 Costo–efectividad De Los Ácidos Grasos Omega 3 Como Coadyuvante De La Simvastatina En El Tratamiento De La Hipertrigliceridemia

    Nov 1, 2011, 00:00

  • PIH19 Public Health Costs Associated with Outbreaks of Meningoccocal Disease- A Systematic Review

    Nov 1, 2011, 00:00

  • PMS40 Economic Evaluation of Etanercept in Rheumatoid Arthritis from the Public Payer perspective in Brazil

    Nov 1, 2011, 00:00

  • PRS1 COST-Effectiveness Of Varenicline Versus Existing Smoking Cessation Strategies in Brazil from the Public Perspective, Using the Benesco Model

    Nov 1, 2011, 00:00

  • PND19 Cost Of The Relapse Of Multiple Sclerosis In Spain

    Nov 1, 2011, 00:00

  • PHP110 Utilization of Physiotherapy Services in Hungary

    Nov 1, 2011, 00:00

  • PSU10 Economic Evaluation of Magnetic Resonance Guided Focused Ultrasound in Patients with Uterine Fibroids in Germany

    Nov 1, 2011, 00:00

  • PMH71 The Impact of Once-Daily Extended-Release Quetiapine Fumarate (Quetiapine XR) on Length and Costs of Hospitalisation of Patients with Schizophrenia or Bipolar Disorder

    Nov 1, 2011, 00:00

  • PIH28 Economic Evaluation of Pneumococcal Conjugated Vaccines for Argentina

    Nov 1, 2011, 00:00

  • PHP164 A Typology of Outcomes for Health Research

    Nov 1, 2011, 00:00

  • PMS4 Economic Evaluation of Post-Operation orthopedic Surgery of antacid, antihemetic and analgesic Medication after Ketoprophene, Ketorolac, Parecoxib and Tenoxicam in Brazilian Patients

    Nov 1, 2011, 00:00

  • PCV27 Frequency of Adverse Drugs Events (ADES) as Possible Causes of Request of Drugs Not Included in Essential Medicines List in Colombia

    Nov 1, 2011, 00:00

  • PDB6 Educational Interventions in Patients with Type-2 Diabetes Improve Clinical and Metabolic Outcomes and Optimize the Use of Treatment Resources in Argentina- The Prodiacor Study

    Nov 1, 2011, 00:00

  • PMH79 The Impact of Comparative Effectiveness Research on Health and Health Care Spending

    Nov 1, 2011, 00:00

  • PHP98 Exploring Regional Variation in Tariffs/Public Prices Across Autonomous Communities in Spain- The Case of Diagnosis Related Groups and ICD-9 Diagnostic Codes

    Nov 1, 2011, 00:00

  • PIN112 Use of Dynamic Models to Measure Health Outcomes of Pneumococcal Vaccination in Spanish Adult Population

    Nov 1, 2011, 00:00

  • PIN79 Cost-Utility Analysis of Tenofovir in Comparison with Other Nucleoside Analogues (AN) in Chronic Hepatitis B (CHB) Treatment

    Nov 1, 2011, 00:00

  • PSY43 The Translation and Linguistic Validation of the Treatment Related Impact Measure – Weight (Trim-Weight)

    Nov 1, 2011, 00:00

  • PGI3 Current Treatments for Chronic Hepatitis B- A Systematic Review

    Nov 1, 2011, 00:00

  • PIH29 the Cost Effectiveness of Clinically Proven Treatment Strategies for Attention-Deficit/Hyperactivity Disorder (ADHD) in Adult Patients

    Nov 1, 2011, 00:00

  • PHP89 Detection of Medication Errors in the Thai FDA Database of Adverse Drug Reactions Reports

    Nov 1, 2011, 00:00

  • PMS23 Analysis of Indirect Costs for Care of Rheumatoid Arthritis Patients Using Large Cohort Database, Iorra, in Japan

    Nov 1, 2011, 00:00

  • PMD46 Development of A Standard Reimbursement Dossier for the Evaluation of Effectiveness and Cost-Effectiveness of A New Medical Device (Nebulizer Mini-plus)

    Nov 1, 2011, 00:00

  • PHP9 Preditores Da quantidade De Medicamentos Tomados Em Pessoas Com DoenÇa Crónica

    Nov 1, 2011, 00:00

  • PHP161 Towards an Efficient National Drug Policy in the Russian Federation

    Nov 1, 2011, 00:00

  • PIN88 Late Immunization Doses Received by Children Younger than Two Years

    Nov 1, 2011, 00:00

  • PMH83 Estimating Utilities in Schizophrenic and Bipolar Patients from Disease-Specific or Generic Instruments Assessing Patients' Health States- Where are the Differences?

    Nov 1, 2011, 00:00

  • PDB42 Economic Evaluation of Recombinant Human FSH in Comparison with Urinary HMG in Assisted Reproduction in the Greek Setting

    Nov 1, 2011, 00:00

  • PCV16 Guidelines Adherent Pharmacotherapy Resulted in Better Hypertension Control

    Nov 1, 2011, 00:00

  • PIH60 Changes in Blood Coagulation Properties Measured by Thrombelastometry During Spiroergometry in Sportsmen and in Sportswomen

    Nov 1, 2011, 00:00

  • PND46 The Huntington Quality of Life Instrument (H-QOL-I)- Cross-Cultural Validation in Germany, Poland and USA

    Nov 1, 2011, 00:00

  • PSS1 Evaluacion Economica De Fototerapia De Banda Angosta O Fotoquimioterapia Para El Tratamiento De Psoriasis Desde La Perspectiva Del Instituto Mexicano Del Seguro SOCIAL

    Nov 1, 2011, 00:00

  • PSY4 Modelo De Costo Beneficio De Lidocaina En Parche Al 5% Versus Pregabalina 300 Mg Y 600 Mg Al Día Para El Tratamiento De La Neuralgia Postherpética

    Nov 1, 2011, 00:00

  • PIN29 Linezolid Versus Vancomycin for Skin and Soft Tissue Infections by Methicilin-Resistant Staphylococcus Aureus- A Cost Comparison Analysis Under the Private Payer Perspective in Brazil

    Nov 1, 2011, 00:00

  • PMD13 Cost Analysis of Vascular Closure Devices (VCD) in the United States

    Nov 1, 2011, 00:00

  • PMH14 Speed of Detection of Adverse Events in Spontaneous Adverse Event Databases Compared with Epidemiological Studies- Two related Cases

    Nov 1, 2011, 00:00

  • PMS1 Meta-analisis De La Efectividad Y Seguridad Del Uso De Celecoxib En El Manejo Del Dolor Cronico vs Otros Cox-2 En Pacientes Con Osteartritis O Artritis reumatoide

    Nov 1, 2011, 00:00

  • PIH4 Analisis De Costo-Efectividad Del Uso De Levonorgestrel-Uis Frente A Otros Tratamientos En Menorragia Idiopatica

    Nov 1, 2011, 00:00

  • PHP1 Improving Patient Safety in the UK and Engaging Patients in research- A New Model for the NHS?

    Nov 1, 2011, 00:00

  • PIN53 Cost-Effectiveness Analysis of Pegylated Interferon Alpha-2A Versus Pegylated Interferon Alpha-2B in the Treatment of Chronic Hepatitis C Patients in Poland

    Nov 1, 2011, 00:00

  • PHP6 Cuadro Básico Y CatÁlogo De Medicamentos Del Sector Salud- Es Actualmente Un referente Para Las instituciones PÚblicas Y/O cumple Con Los Objetivos De Su Creación

    Nov 1, 2011, 00:00

  • PMH43 Association Between Antidepressant-Related Weight Gain and Medication Adherence in Employed Individuals by Gender

    Nov 1, 2011, 00:00

  • PCN191 Economic Evaluation of XELOX vs FOLFOX4 as Adjuvant Treatment for Patients with Stage III Colon Cancer in south Korea

    Nov 1, 2011, 00:00

  • PGI26 Evaluating the Impact of Gastrointestinal Episodes on the Health-related Quality of Life of Solid Organ Transplant Recipients- Validation of the SIGIT-QoL® Questionnaire – the Mypaciente 1 2 Studies

    Nov 1, 2011, 00:00

  • PCV83 A Cost-Effectiveness Analysis of Ticagrelor in Patients with Acute Coronary Syndrome in Greece

    Nov 1, 2011, 00:00

  • PUK11 Preliminary Cost-Minimization Analysis of Continuous Versus Intermittent Renal Replacement Therapy in Intensive Care Patients Experiencing Acute Renal Failure

    Nov 1, 2011, 00:00

  • PHP160 Introducing the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP)- A Bridge Between Medicines Regulation and Health Outcomes Research

    Nov 1, 2011, 00:00

  • PCN153 Cost of Hospital Care in Population of Patients with Neoplasms in Poland

    Nov 1, 2011, 00:00

  • PUK12 Medical Resource Use in US Patients Diagnosed with Chronic Kidney Disease with and Without Diabetes Mellitus

    Nov 1, 2011, 00:00

  • PGI17 Cost of Outpatient Endoscopic Capsule (EC) Procedure in Brazil- A Study from a Payer'S Perspective

    Nov 1, 2011, 00:00

  • PHP65 Pharmaceutical Expenditure in Portugal – Policies and Impact

    Nov 1, 2011, 00:00

  • PRM24 Scan- An Integrated System for Market Access of New Drugs in Italy

    Nov 1, 2011, 00:00

  • PCN79 Cost Effectiveness of Erlotinib in First Line Treatment of Advanced Non Small Cell Lung Cancer (NSCLC) in Vulnerable Elderly Patients- An Economical Analysis of a prospective Phase 2 Study (GFPC 0505)

    Nov 1, 2011, 00:00

  • PMH56 Negative Symptoms Have Greater Impact on Functioning Than Positive Symptoms in Schizophrenia- Analysis of Catie Data

    Nov 1, 2011, 00:00

  • PCV34 Improving Global Vascular Risk Management (GVRM) Using the COSEHC Cardiovascular Risk Assessment Tool

    Nov 1, 2011, 00:00

  • DA2 A Choice that Matters- Comparing Methods of Data Synthesis in Cost-Effectiveness Modelling

    Nov 1, 2011, 00:00

  • PDB54 HRQoL and Clinical Impact of Mild Patient-Reported Hypoglycaemic Episodes in Five European Countries- Extent of Agreement Between Physician- and Patient-Reported Hypoglycaemic Episodes

    Nov 1, 2011, 00:00

  • PMD30 Cost-Effectiveness Analysis of Pulmonary Vein Isolation (PVI) Using A Novel Cryo Energy-Based Balloon Catheter- A High-Value procedure for Payers?

    Nov 1, 2011, 00:00

  • PGI27 Sleep Disturbance and Quality of Life Among Hepatitis C Infected Individuals

    Nov 1, 2011, 00:00

  • PMS65 Quality of Life for Thai Hip Fracture Patients- Assessments with Medical outcomes Study, a 36-Item Short form Survey (MOS SF-36) and One-Year Health Care Resource Utilization in a Public Hospital

    Nov 1, 2011, 00:00

  • PRS18 Economic Burden of Cystic Fibrosis in the US- Costs of Care By Disease Severity and Age

    Nov 1, 2011, 00:00

  • PIN109 Modelling the Policy of Managing Seasonal Influenza in the UK

    Nov 1, 2011, 00:00

  • PCN159 Diagnostics and Treatment of Patients with Non-Small-Cell Lung Cancer in Daily Practice

    Nov 1, 2011, 00:00

  • PCN194 The Use of Large GPs Longitudinal Database in the Reasearch of Causal Associations Among Pathologies- The Case of Diabetes and Cancer Incidence

    Nov 1, 2011, 00:00

  • PCV94 Dronedarone is Cost-Effective for the Prevention of Downstream Cardiovascular Morbidity and Mortality in Australian Patients with Atrial Fibrillation

    Nov 1, 2011, 00:00

  • PMS61 Rapid Reductions in Fatigue and Sleep Problems and Correlation with Improvements in Patient-Reported Outcomes in Patients with Active RA Treated with Certolizumab Pegol in the realistic 12-Week Phase IIIB Randomised Controlled Study

    Nov 1, 2011, 00:00

  • PIN8 Evaluacion Economica De La Extension De Profilaxis Contra CMV De 100 A 200 Dias En Receptores De Trasplante Renal Con Alto Riesgo (D+ / R−)

    Nov 1, 2011, 00:00

  • PIN16 Rates and Predictors of Gonorrhea Re-Screening Among Privately Insured Patients with Gonorrhea in 2007-2009

    Nov 1, 2011, 00:00

  • PHP21 Medical Services Cost Influence on the Rationality of New Medical Technology Introduction

    Nov 1, 2011, 00:00

  • PCV32 Population Attributable Risk (PAR) of Macrovascular Events Associated with HbA1C, Blood Pressure or Weight in Patients with Type 2 Diabetes Mellitus- Evidence from a Dutch Cohort

    Nov 1, 2011, 00:00

  • PCN88 Economic Model of Granulocyte-Colony Stimulating Factor (G-CSF) in Primary (PP) and Secondary Prophylaxis (SP) of Febrile Neutropenia (FN) in Non-Hodgkin'S Lymphoma (NHL) Patients Undergoing Chemotherapy in France

    Nov 1, 2011, 00:00

  • PIN66 Cost of Virologic Failure with Etravirine and Raltegravir in the Brazilian National AIDS Program

    Nov 1, 2011, 00:00

  • PMD72 Mamma Carcinoma – Data analyses and Classification of Treatment in Austria

    Nov 1, 2011, 00:00

  • PHP125 Clinical Trial Learning Curves May Impact Both Clinical and Economic Outcomes, and Influence Health Technology Assessment and Reimbursement Decision Making

    Nov 1, 2011, 00:00

  • PIN90 Discrete Choice Experiments (DCES) in HIV/AIDS Treatment- Expert Judgement in Comparison to Patient Preferences

    Nov 1, 2011, 00:00

  • PRS5 Analysis Of Efficacy and Safety of Dornase Alfa in The Treatment of Cystic Fibrosis

    Nov 1, 2011, 00:00

  • PMH17 The Economic and Social Consequences of Schizophrenia Treatment with Seroquel XR® (Quetiapine Prolonged Release Tablets) in Poland- Aanalysis of the Impact on the Health Care System

    Nov 1, 2011, 00:00

  • PRM15 The Outcome of ISPOR European and International Congresses Between 2005-2009

    Nov 1, 2011, 00:00

  • PDB67 Treatment Patterns and Health Outcomes Among Type 2 Diabetes with Comorbid Obesity in France, Germany, And UK

    Nov 1, 2011, 00:00

  • PIH3 Respiratory Syncytial Virus Hospitalizations in the Canadian Registry for Synagis (CARESS)

    Nov 1, 2011, 00:00

  • PMS8 Cost-Effectiveness analysis of Etanercept versus Available anti-Tnf and Il-6 Blockers for Treating Rheumatoid Arthritis in Guatemala

    Nov 1, 2011, 00:00

  • PCN105 Economic Evaluation of Panitumumab and Cetuximab in the Treatment of Patients with EGFR Expressing mCRC with Non-Mutated (Wild-Type) KRAS in Gree A Cost Minimization Analysis

    Nov 1, 2011, 00:00

  • PSY35 Economic Evaluation of Darbepoetin Alfa in the Management of End Stage Renal Disease (ESRD) Patients with Anemia in the Greek Nhs Setting

    Nov 1, 2011, 00:00

  • PMH24 Economic Burden of Mental Illnesses in Pakistan

    Nov 1, 2011, 00:00

  • PCN151 Value of Outcomes Research to Inform Reimbursment Decision-Making Illustrated by an Observational Study in Chronic Lymphocytic Leukemia

    Nov 1, 2011, 00:00

  • PCN85 Cost-Effectiveness of A Human Papillomavirus Vaccination of Boys

    Nov 1, 2011, 00:00

  • PDB73 Impact of Epidemiological and Economic Factors on Insulin Total Sales in the UK Diabetic Market

    Nov 1, 2011, 00:00

  • PIH32 What are the Factors Influencing Parental Apprehension About Consenting Children to Participate in Pediatric Observational Studies? A Survey Conducted in France with in Fine Pharma, a Pharmacist Network

    Nov 1, 2011, 00:00

  • RM1 Comparing the Use of Dynamic and Static Infectious Disease Models in Latin America with North America, Europe, Asia and other Regions

    Nov 1, 2011, 00:00

  • PRM34 Examining Variations in Item Structure and Content in Pro Instruments, or, There Must be 50 Ways to Express Your Distress

    Nov 1, 2011, 00:00

  • PCV105 Using Theory of Reasoned Action Variables to Predict and Improve Statin Adherence

    Nov 1, 2011, 00:00

  • PCN30 Comparative Analysis of Cost and Resource Use Among Patients With Brain Metastasis by Initial Primary Cancer

    Nov 1, 2011, 00:00

  • PCN14 Systematic Review of Clinical Efficacy and Safety outcomes of Anti-Angiogenic Therapies for Metastatic Colorectal Cancer

    Nov 1, 2011, 00:00

  • PIN68 Cost- Effectiveness Analysis of Human Papillomavirus Vaccination Program in Russia

    Nov 1, 2011, 00:00

  • PSY42 Chronic Pain- Patient Treatment Preferences - a Discrete Choice Experiment

    Nov 1, 2011, 00:00

  • PDB6 Description of Comorbidities and Body Mass Index in US Adults with and Without Diabetes from the Medical Expenditure Panel Survey, 2008

    Nov 1, 2011, 00:00

  • PHP94 Analysis of Results of the Reference Pricing of Turkey

    Nov 1, 2011, 00:00

  • PCN5 Efectividad CLÍnica Y Costo-Efectividad Del Tratamiento De Segunda LÍnea Para Carcinoma MetastÁsico De CÉlulas Renales

    Nov 1, 2011, 00:00

  • PRS61 Age has No Significant Impact on Health-Related Quality of Life in Patients Hospitalized for COPD Exacerbations

    Nov 1, 2011, 00:00

  • PRM4 Measuring Comorbidity in Administrative Data

    Nov 1, 2011, 00:00

  • PSY37 Assessment of the Global Cost of Transfusion in French Orthopedic Surgery Wards

    Nov 1, 2011, 00:00

  • MT4 Mixed Treatment Comparisons Using Aggregate- and individual-Participant Level Data- An Efficient Use of Evidence for Cost-Effectiveness Modelling

    Nov 1, 2011, 00:00

  • PSY21 Predictors of Duloxetine Adherence and Persistence in Patients with Fibromyalgia

    Nov 1, 2011, 00:00

  • PSY55 Cost of Autologous and Allogeneic Stem Cell Transplantations for Haematological Disease- A Dutch Multicentre Daily Practice Study

    Nov 1, 2011, 00:00

  • PCN150 Willingness to Pay for A Reduction in Risk of Treatment Side Effects in Patients with Metastatic Breast Cancer

    Nov 1, 2011, 00:00

  • PSY13 Comparing Top Reasons for Primary Care or Specialty Care Visits Among Fibromyalgia Patients Initiated Duloxetine Versus Pregabalin

    Nov 1, 2011, 00:00

  • PCV21 Clinical Efficacy of Bisoprolol Compared to Atenolol in Reducing the In-Clinic and Ambulatory Blood Pressure in Hypertensive Patients

    Nov 1, 2011, 00:00

  • PRS5 Cost-Effectiveness of Varenicline vs Existing Smoking Cessation Strategies in Dominican republic Using the Benesco Model

    Nov 1, 2011, 00:00

  • PIN5 Patient and Clinician Perceived Benefit of Early Consumption of Famciclovir for the Treatment of Herpes Outbreaks

    Nov 1, 2011, 00:00

  • PMD71 Resource Use Caused by in-office Follow-up Visits for Cardiac Implantable Electrical Devices (CIED) in Germany and the United Kingdom

    Nov 1, 2011, 00:00

  • PDB7 Prevalence, Demographics and Treatment Characteristics of Diabetes with Lantus, NPH and Premix Insulin in a Representative Canadian Cohort

    Nov 1, 2011, 00:00

  • PHP81 Funding Sources Analysis Results (Regional and Federal Levels) of Pharmaceutical Markets per Regions of Russian Federation

    Nov 1, 2011, 00:00

  • PRS55 Further Developments of the Living with Chronic Obstructive Pulmonary Disease (LCOPD)

    Nov 1, 2011, 00:00

  • PHP19 Increased Market Share of Private, For-Profit Health Care Providers From the Hungarian Health Insurance Budget Between 2006-2009

    Nov 1, 2011, 00:00

  • PMS10 Cost-Effectiveness of Duloxetine Compared to Pregabaline in Patients with Fibromyalgia from the Public Health Care System perspective in México

    Nov 1, 2011, 00:00

  • PHP67 Tendering for Outpatient Prescription Pharmaceuticals- What Can Be Learned from Current Practices in Europe?

    Nov 1, 2011, 00:00

  • PCN148 Estimating Quality of Life in Advanced Melanoma; A Comparison of Standard Gamble, SF-36 Mapped, and Eortc QLQ-C30 Mapped Utilities

    Nov 1, 2011, 00:00

  • PCN141 Quality of Life in Small Cell Lung Cancer- Results of an Open-Label Phase III Clinical Trial

    Nov 1, 2011, 00:00

  • PRM5 Novel Patient Reported Outcomes and Data Tool for Chronic Disease Management (PROCDIM)- Case in Point Prostate Cancer

    Nov 1, 2011, 00:00

  • PRS75 Health Technology Appraisal of New Drugs- Are we Getting it Right?

    Nov 1, 2011, 00:00

  • PMS13 Economic Model of Workplace Impacts of anti-Tnf therapy for Rheumatoid Arthritis in Brazil

    Nov 1, 2011, 00:00

  • PCN143 Electronic Patient-Reported Outcome Monitoring in Testicular Cancer Patients

    Nov 1, 2011, 00:00

  • PND22 A Cost-of-Illness Analysis of Myasthenia Gravis in Greece

    Nov 1, 2011, 00:00

  • PMD52 Workload in German Hospitals Caused by Routine Follow-up Services for Cardiac Implantable Electrical Devices (CIED)

    Nov 1, 2011, 00:00

  • PGI13 Evaluation of the Clinical and Economic Burden of Chronic Constipation in Belgium

    Nov 1, 2011, 00:00

  • PCN3 Estimacion De La Carga De Los Tumores Neuroendocrinos En Colombia

    Nov 1, 2011, 00:00

  • PND28 Cost-Effectiveness Analysis of Interferons and Glatiramer Acetate as First Line Treatments in Remitting – Relapsing Multiple Sclerosis Spanish Patients

    Nov 1, 2011, 00:00

  • PSY3 The Potential Impact of Obesity Degree on Diabetes, Heart Attack, Hypertension, Chronic Anxiety and Depression in Adult Spanish Population

    Nov 1, 2011, 00:00

  • PCV4 Analisis Costo Efectividad En El Largo Plazo De Los Stents Liberadores De Farmaco vs Stents Convencionales En Pacientes Con Cardiopatia Isquemica En El Imss

    Nov 1, 2011, 00:00

  • PHP13 A Survey of Pricing Trends Around the World

    Nov 1, 2011, 00:00

  • PMS7 The Osteoporotic Fracture Incidence in Elderly Women of Taiwan

    Nov 1, 2011, 00:00

  • PSS16 Cost of Blindness in Austria

    Nov 1, 2011, 00:00

  • PSS3 Un Estudio De Costo-Efectividad Para Evaluar El Tratamiento Con N-Acetil Cisteína En Pacientes Con Esclerosis Sistémica

    Nov 1, 2011, 00:00

  • PSY23 Pregabalin is Associated with Lower Health Care Costs and Less Absenteeism than Gabapentin when Added to the Treatment of Neuropathic Pain

    Nov 1, 2011, 00:00

  • PCV124 Reference Pricing, Originator Drugs and Consumerxs Choice

    Nov 1, 2011, 00:00

  • PCV139 Epidemiology and Economic Burden of Atrial Fibrilation to the Public Health Care System in Brazil

    Nov 1, 2011, 00:00

  • PCV119 Relationship Between Quality of Life and Level of Cardiovascular Risk and Comorbidities in Spanish Hipertensive Patients-Alhambra Study

    Nov 1, 2011, 00:00

  • PCV41 The Budgetary Impact of Implementing A Telehealth Home Monitoring System for Chronic Heart Failure Patients in a Typical UK Primary Care Trust

    Nov 1, 2011, 00:00

  • PND64 Cost-Minimization Analysis of IFNB-1B and Fingolimod among Multiple Sclerosis Patients in Germany

    Nov 1, 2011, 00:00

  • PIN56 Cost-Effectiveness Model to Evaluate 200-Day vs 100-Day Treatment with Valganciclovir Prophylaxis to Reduce Cytomegalovirus Disease in High-Risk (D+/R-) Kidney Transplant Recipient in Spain

    Nov 1, 2011, 00:00

  • PMS39 Economic Evaluation of Tocilizumab for the Treatment of Systemic Juvenile Idiopathic Arthritis in Mexico

    Nov 1, 2011, 00:00

  • PIN6 Evaluacion COSTO-Efectividad Del Uso De Linezolid En El Tratamiento De Neumonias Nosocomiales En MÉXICO

    Nov 1, 2011, 00:00

  • PDB11 Glycemic Outcomes Among Patients Receiving Exenatide BID or Liraglutide for Type 2 Diabetes in Clinical Practi A Retrospective Analysis of the GE Centricity EMR Data

    Nov 1, 2011, 00:00

  • PRS28 Adherence to Current Guidelines for Chronic Obstructive Pulmonary Disease (COPD) in Subjects Treated with Combination of Long-Acting β2-Agonist (LABA), LONG-Acting Muscarinic Antagonist (LAMA) or Inhaled Corticosteroids (ICS)

    Nov 1, 2011, 00:00

  • PCV135 Low Lipoprotein Cholesterol Goal Attainment in Dyslipidemic Patients with Existing Statin therapy- A Chart Extraction-Based Approach

    Nov 1, 2011, 00:00

  • PCV74 Is Treatment of Depression Cost Effective in the Management of People with CHD and Diabetes- A Systematic Review of the Economic Evidence

    Nov 1, 2011, 00:00

  • PIN20 Clinical and Economical Impact of Pneumococcal Vaccination in Spanish Adult Population Measured by a Dynamic Model

    Nov 1, 2011, 00:00

  • PIN52 Cost-Effectiveness of Rifampicin-Based Continuation Phase of Tuberculosis Treatment in Uganda

    Nov 1, 2011, 00:00

  • PHP21 Adoption of New Medicines in the OECD- Regulation, Innovation and Scale

    Nov 1, 2011, 00:00

  • PCN92 The Cost-Effectiveness of Nanoparticle Albumin-Bound Paclitaxel Compared to Solvent-Based Paclitaxel in Women with Metastatic Breast Cancer

    Nov 1, 2011, 00:00

  • PCV111 Economic Burden and Health- Related Quality of Life in European Patients with Peripheral Arterial Disease

    Nov 1, 2011, 00:00

  • PMH66 12-Year Trend Analysis on the Characteristics, Primary Payer, and Prescribed Medications of Physician-Office Visits for Patients with Dementia in the United States

    Nov 1, 2011, 00:00

  • PRS35 Economic Evaluation of Indacaterol Versus Tiotropium or Formoterol for Patients with Moderate to Severe Copd in Greece

    Nov 1, 2011, 00:00

  • PCV132 Do Atrial Fibrillation (AF) Patients Get Oral Anticoagulation (OAC) as Guidelines Recom-Mend? An Analysis of German Health Insurance Claims Data

    Nov 1, 2011, 00:00

  • PMS25 Evaluation of Direct Costs for the Treatment of Active Juvenile Rheumatoid Arthritis Using Biologics

    Nov 1, 2011, 00:00

  • PCN15 Dance as Physiotherapy in the Rehabilitation of Women Suffering from Tumour

    Nov 1, 2011, 00:00

  • PCN125 Elicitation of Health State Utilities in Neuroendocrine Tumours

    Nov 1, 2011, 00:00

  • DA4 Finding Treatment Effects within Subgroups when Using the propensity Score to Control for Selection Bias- A Monte Carlo Simulation Study

    Nov 1, 2011, 00:00

  • PMS47 The Long Term Cost-Effectiveness of Golimumab for the Treatment of Severe, Active Ankylosing Spondylitis in Adults Who Have Responded Inadequately to Conventional Therapy

    Nov 1, 2011, 00:00

  • PIH52 Medicine Prescribing Patterns in HIV/AIDS and Non-HIV/AIDS Children- A Comparitive Study in the Private Health Care Sector of South Africa

    Nov 1, 2011, 00:00

  • PND34 Cost-Utility Analysis of Lacosamide Adjunctive Therapy in the Treatment of Patients With Refractory in the Slovak Republic

    Nov 1, 2011, 00:00

  • PCV55 Clinical and Economical Burden of Oropharyngeal Dysphagia Among Stroke Survivors in Europe and North America

    Nov 1, 2011, 00:00

  • PMH6 Effectiveness of Long-Acting Iinjectable Risperidone and Oral Atypical Antipsychotics in a 24-Months Observational Study in Adult Patients with Schizophrenia in Germany

    Nov 1, 2011, 00:00

  • MA4 Modelling EQ-5D Health State Values- Developing A Limited Dependent Variable, Mixture Modeling Approach

    Nov 1, 2011, 00:00

  • PRS73 Systematic Review of the Guidelines on the Prevention of Allergic Manifestations in Children

    Nov 1, 2011, 00:00

  • PIH7 The Efficiency of in Vitro Fertilization in Hungary 2000-2010

    Nov 1, 2011, 00:00

  • PCN181 The Health Related Quality of Life Data (HRQoL) for Health Technology Assessment (HTA) Process in Europe- Their Utilization and Impact on Opinions across HTA Agencies

    Nov 1, 2011, 00:00

  • PMS60 Experiences of Patients with Rheumatoid Arthritis in the US and UK- A Cross-Cultural Comparison

    Nov 1, 2011, 00:00

  • PSS44 Using Structural Equation Modeling to Investigate the Association of Treatment Satisfaction With Disease Severity and Health Related Quality of Life

    Nov 1, 2011, 00:00

  • PRM61 Sample Size Estimation for Prospective Observational Studies

    Nov 1, 2011, 00:00

  • PMD38 Cost-Effectiveness of the Cardiovascular Marker ST2 in Providing Risk Stratification After Acute Heart Failure

    Nov 1, 2011, 00:00

  • PHP71 Effect of SIADH on Patient outcomes and Health Care Resource Utilization in Hospitalized Patients

    Nov 1, 2011, 00:00

  • PSY28 Cost-Effectiveness Analysis Comparing Epidural, Patient-Controlled Iv Morphine, and Continuous Wound Infiltration for Postoperative Pain Management After Abdominal Surgery

    Nov 1, 2011, 00:00

  • PCN8 Incidence, Predictive Factors, and Infection Complications of Prolonged Neutropenia in R-CHOP/CHOP Treated Diffuse Large B-Cell Lymphoma Patients

    Nov 1, 2011, 00:00

  • PCN98 Estimating the Potential Cost-Effectiveness of Human Papillomavirus (HPV) Vaccination in Germany Using A Dynamic Transmission Model

    Nov 1, 2011, 00:00

  • PDB76 Knowledge, Medication Adherence and Glycemic Control Among Patients with Type 2 Diabetes Mellitus

    Nov 1, 2011, 00:00

  • IN2 Chronic Hepatitis C Treatment For Genotype 2 Or 3- COST-Effectiveness Analysis of Peg as First Line Treatment With the Brazilian Protocol

    Nov 1, 2011, 00:00

  • HS2 Analisis De Costos Del Programa Ampliado De Inmunizaciones En Colombia 2009

    Nov 1, 2011, 00:00

  • PCN58 The Cost of Strong Opioid Treatment of Oncological Pain in the Brazilian Private Health Care System

    Nov 1, 2011, 00:00

  • PDB9 Analisis De Costo–Efectividad Del Uso De Detemir En Diabetes Tipo 2 Frente Al Riesgo De Presentar Eventos Cardiovasculares Y Muerte

    Nov 1, 2011, 00:00

  • PRM64 The Role of the Instrument Developer in the Translation of Patient Reported Outcome Measures

    Nov 1, 2011, 00:00

  • PRS57 Patient Reported Burden of Asthma Bronchiale in the Slovak Republic

    Nov 1, 2011, 00:00

  • PND49 Initial Psychometric Properties of the Eurodolmed Questionnaire- A New Instrument to Measure Neuropathic Pain in Patients with Spinal Cord Injury (SCI) Based on Pain Intensity, Pain Interference and Pain Descriptors

    Nov 1, 2011, 00:00

  • PMS38 A Structured Literature Review of Rheumatoid Arthritis Economic Models for Biologics

    Nov 1, 2011, 00:00

  • PCV88 Long Term Cost-Effectiveness Analysis of Ticagrelor in Patients with Acute Coronary Syndromes from a Brazilian Public Healthcare perspective Based on Data from the Plato Trial

    Nov 1, 2011, 00:00

  • PSS43 A Systematic Review of Observational Studies of Patients With Ocular Hypertension or Glaucoma Receiving Long Term Topical Eye Therapies

    Nov 1, 2011, 00:00

  • PMH65 The Challenge of Adherence and Individualized Treatment in Severe Mental Disorders – A Nordic Perspective

    Nov 1, 2011, 00:00

  • PRM41 are General Population Data Suitable for Approximating Baseline Utility Values in Economic Models?

    Nov 1, 2011, 00:00

  • PRS31 Economic Evaluation of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) from the Public Payer Perspective in Brazil

    Nov 1, 2011, 00:00

  • PSS18 Direct Economic Burden of Regular Intravitreal Injections for the Treatment of Retina Diseases in Three European Countries

    Nov 1, 2011, 00:00

  • PDB55 Translation and Validation Study of 14-Item Michigan Diabetes Knowledge Test (MDKT)- The Urdu Version

    Nov 1, 2011, 00:00

  • PMS2 Risk and Cost of Infections in Rheumatoid Arthritis Patients Treated with anti-TNF therapy in Alberta, Canada

    Nov 1, 2011, 00:00

  • CV3 Análisis De Costo Efectividad En El Cierre De La Comunicación Interatrial Ostium Secundum- Técnica Percutánea Versus Quirúrgica

    Nov 1, 2011, 00:00

  • PSU1 Suprapubic Tube Placement Related Bowel Injury- Proposed Guidelines for Open Placement

    Nov 1, 2011, 00:00

  • PMH53 Follow-up of Health-Related Quality of Life in Young Heroin Users

    Nov 1, 2011, 00:00

  • PHP20 Market Access Barriers for Biosimilars in Spain and Germany- Epoetin Alfa Example

    Nov 1, 2011, 00:00

  • PIN38 Guideline Evaluation of Costs Related to Chronic Hepatitis C and Antiviral Treatment Strategies

    Nov 1, 2011, 00:00

  • PRM4 A MIXED-Effects Piecewise Linear Model Of The Rate Of Lung Function Decline Before And After Inhaled Corticosteroids In An Observational Study Of Children With Cystic FIBROSIS

    Nov 1, 2011, 00:00

  • PMD62 Validation of A Patient-Reported Outcome (PRO) Measure and A Clinician-Reported Outcome (CRO) Measure to assess Satisfaction and Preference with Pharmacological Stress Agents for Single Photon Emission Computed tomography (SPECT) Myoc ...

    Nov 1, 2011, 00:00

  • PRS65 The Effect of Omalizumab on Unscheduled Healthcare Resource Utilisation and Health-Related Quality of Life in UK Clinical Practi The Apex Study

    Nov 1, 2011, 00:00

  • PHP63 Savings on Pharmaceutical Expenditure in Greek NHS Hospitals Under the Shadow of the International Monetary Fund (IMF)

    Nov 1, 2011, 00:00

  • PSS20 Annual Cost of Biological Therapies for the Treatment of Moderate to Severe Plaque Psoriasis in Spain

    Nov 1, 2011, 00:00

  • PND8 Prevalence and Procedure for Vertigo Follow-up in France

    Nov 1, 2011, 00:00

  • HG4 The Value of Heterogeneity for Cost-Effectiveness Subgroup Analysis- Theoretical Framework and Application

    Nov 1, 2011, 00:00

  • CN4 Heterogeneity In Predicting The Future Impact Of Technologies To Control Hepatocellular Carcinoma (HCC)- A Comparison Of Stakeholder Views From Europe And Asia

    Nov 1, 2011, 00:00

  • PCV48 Clinical Outcomes and Costs Associated with Stroke in Patients with Non-Valvular Atrial Fibrillation

    Nov 1, 2011, 00:00

  • PMS16 Potential Cost Saving of Epoetin Alfa Compared to Autologous Blood Donation or to No-Blood-Conservation-Strategy Before Elective Hip or Knee Surgery Due to reduction in Allogeneic Blood Transfusions and Its Side Effects

    Nov 1, 2011, 00:00

  • PMH33 The Cost-Effectiveness of Paliperidone ER in Spain

    Nov 1, 2011, 00:00

  • PUK2 Cost Per Successful Response Of Standard Treatment Plus Cinacalcet Versus Standard Treatment Alone In Patients With Secondary Hyperparathyroidism In MEXICO

    Nov 1, 2011, 00:00

  • PMS9 What is the Value of the New Kid on the Block?- tocilizumab versus Abatacept for Rheumatoid Arthritis in Colombia

    Nov 1, 2011, 00:00

  • PRM69 Measuring Relative Effectiveness in Europe- As in the USA, Here Too, It is Time to Turn the QALY Page

    Nov 1, 2011, 00:00

  • PRS56 Assessing Patient Report of Function- Content Validity of the Functional Performance Inventory-Short form (FPI-SF) in Patients with Chronic Obstructive Pulmonary Disease

    Nov 1, 2011, 00:00

  • PCN68 Cost-Effectiveness and Quality of Life Analysis of the Multicenter Itac02-01 Study- Prospective Randomized Comparison of Reduced Intensity Versus Non-Myeloablative Conditioning Regimen for Matched Related Allogeneic Stem Cell Transpla ...

    Nov 1, 2011, 00:00

  • PHP27 The Economic Benefits of Implementing A Unit Dose Drug Dispensing System at the Hospital Level in the Mexican Institute of Social Security (IMSS)

    Nov 1, 2011, 00:00

  • PRM54 Model and Covariate Visualization Aids for Enhancing the Interpretation of Steps in the High Dimensional Propensity Scoring Adjustment Procedure

    Nov 1, 2011, 00:00

  • PGI8 Cost Analysis and Incidence of Adverse Gastrointestinal Events Following Bisphosphonate Treatment Among Women with Osteoporosis in Taiwan

    Nov 1, 2011, 00:00

  • PCN10 Comorbid Cardiovascular Diseases in Patients with Metastatic Colorectal Cancer

    Nov 1, 2011, 00:00

  • PIN35 Costs of Managing Genital Warts in the UK

    Nov 1, 2011, 00:00

  • PDB74 Title- Implementation of Diabetes Programme Budget Marginal Analysis (PBMA) Exercise in an English Primary Care Trust (PCT)

    Nov 1, 2011, 00:00

  • PIN11 Evaluacion Economica De Las Vacunas Conjugadas De Pneumococo Para Peru

    Nov 1, 2011, 00:00

  • PRM67 What EPRO Modality is Appropriate for Your Study?

    Nov 1, 2011, 00:00

  • PND57 Effect of Treatment Timing on Risk of Institutionalization Among Patients with Alzheimer'S Disease

    Nov 1, 2011, 00:00

  • PRS38 The Cost-Effectiveness of Roflumilast for COPD in Sweden

    Nov 1, 2011, 00:00

  • PND38 International Comparison of Huntington Disease (HD) Burden

    Nov 1, 2011, 00:00

  • PIN111 Dynamic Modeling of Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccination Against Streptococcus Pneumoniae in Taiwan

    Nov 1, 2011, 00:00

  • PIN103 A Comparison of Investments for Different Prevention Programs- Respiratory Syncytial Virus Prophylaxis Versus Human Papilloma Vaccine

    Nov 1, 2011, 00:00

  • PSY36 Modelling the Cost-Effectiveness of Orlistat as a Treatment for Obesity in Primary Care

    Nov 1, 2011, 00:00

  • PMS64 Sensitivity of Pro'S to Detect Changes in Quality of Life in Patients Treated with a Biologic Agent

    Nov 1, 2011, 00:00

  • PHP48 Croatian Pharmaceutical Expenditure Before and After Healthcare Reform – Comparison to EU Countries

    Nov 1, 2011, 00:00

  • PMS12 A Budget Impact Model for the Use of Abatacept as a First Biologic Treatment for Rheumatoid Arthritis in Italy

    Nov 1, 2011, 00:00

  • PHP39 Toward a Better Drug Pricing Policy in Korea- Links Between Price Regulation and RD Activities

    Nov 1, 2011, 00:00

  • PMS79 Mixed Treatment Comparison of Biologic Agents in Patients with Rheumatoid Arthritis Who Have responded Inadequately to Methotrexate Therapy in the United Kingdom

    Nov 1, 2011, 00:00

  • PCN122 Disclosing Traditional CM) Use to the Health Care Providers- A Qualitative Study Among Cancer Patients at a Local Hospital in Malaysia

    Nov 1, 2011, 00:00

  • PIN22 Comparison of Two Dynamic Models Predicting Future Burden of Illness of Hepatitis C (HCV) in the EU-5 (France, Germany, Italy, Spain, UK)

    Nov 1, 2011, 00:00

  • PND50 Public Preferences for the Predictive Genetic Test for Alzheimer'S Disease in the United States

    Nov 1, 2011, 00:00

  • PMD58 Provision and Financing of Medical Aids in the Management of Rare Diseases- The Case of Amyotrophic Lateral Sclerosis (ALS)

    Nov 1, 2011, 00:00

  • PSS8 Advanced Cutaneous Melanoma in the UK- A Systematic Review

    Nov 1, 2011, 00:00

  • PMD17 Noble Metal Alloy-Coated Urethral Catheter- A Budget Impact analysis in the Veneto Region of Italy

    Nov 1, 2011, 00:00

  • PMH16 Budgetary Impact Analysis of Buprenorphine/Naloxone (Suboxone®) in Opioid Maintenance Treatment in Spain

    Nov 1, 2011, 00:00

  • PIN1 The Epidemiologic Burden Of Hepatitis C Virus Infection In Latin America

    Nov 1, 2011, 00:00

  • PCN42 Treatment Costs of Bone Metastases in Patients with Lung Cancer- Results From A French Prospective, Observational, Multicenter Study (GFPC 0601)

    Nov 1, 2011, 00:00

  • PSS2 Encouraging The Efficiency Of The National Transplant PROGRAM- Estimating The Cost Of Corneal Transplant To Be Financed By Public Institutions In The Health Sector In MEXICO

    Nov 1, 2011, 00:00

  • PC3 Breast and Prostate Cancer Productivity Costs- A Comparison of the Human Capital Approach and Friction Cost Approach

    Nov 1, 2011, 00:00

  • PIN54 Cost-Effectiveness of 2+1 Dosing of 13-Valent Pneumococcal Conjugate Vaccine Compared with 2+1 Dosing of 10-Valent Conjugate Vaccine in Preventing Pneumococcal Disease in Canada

    Nov 1, 2011, 00:00

  • PHP18 Impacto De La Participacion Del Farmaceutico Como Parte Del Equipo De Salud En El Primer Nivel De atencion sobre Los Costos

    Nov 1, 2011, 00:00

  • PGI29 Quality of Life in Chronic Liver Disease

    Nov 1, 2011, 00:00

  • PCV110 Health-Related Quality of Life After Venous Thromboembolism

    Nov 1, 2011, 00:00

  • PIN65 Health Economic Model on the Costs and Effects of Rota Virus Vaccination in Germany

    Nov 1, 2011, 00:00

  • PMS7 Direct Treatment-Cost of Patients with Rheumatoid Arthritis in Medellin, Colombia

    Nov 1, 2011, 00:00

  • PUK4 COSTO-Efectividad De Intervenciones Para Insuficiencia Renal CRÓnica Terminal En MÉXICO

    Nov 1, 2011, 00:00

  • PHP41 Improving Use of Medicines in the Community Through Interventions

    Nov 1, 2011, 00:00

  • PHP117 The Cost-Effectiveness Threshold- The Results of A Novel Literature Review Method

    Nov 1, 2011, 00:00

  • PCN32 Cost Savings With Bevacizumab Compared to Sunitinib in the Treatment of MRCC

    Nov 1, 2011, 00:00

  • PMS22 The Burden of Illness of Osteoporosis in Canada

    Nov 1, 2011, 00:00

  • PSY10 Budget Impact Analysis of Somatuline Autogel in the Management of Acromegaly in Spain

    Nov 1, 2011, 00:00

  • PCN2 A Retrospective Longitudinal Study of Treatment Patterns and Outcomes Among Patients with Unresectable Stage IIIc/IV Melanoma in Canada (Melody)

    Nov 1, 2011, 00:00

  • PCN29 Budgetary Impact of Adoption of Erlotinib for Lung Cancer in the Private Health Insurance Market in Brazil- A Real World Data Analysis

    Nov 1, 2011, 00:00

  • PSY2 ESTIMACIÓn Del Impacto Financiero En La Salud De La POBLACIÓn Mexicana Derivado De La Obesidad Y El Sobrepeso, 2000-2017

    Nov 1, 2011, 00:00

  • PRS30 Identifying the Patient Population Where Treatment of Severe Allergic Asthma with Omalizumab (XOLAIR®) Exhibits Optimal Cost-Effectiveness in Australia

    Nov 1, 2011, 00:00

  • PND59 A Common Road Map for Rational Clinical and Policy Decisionmaking- Application of the MCDA-Based Evidem Framework to Growth Hormone Use in Patients with Prader-Willi Syndrome

    Nov 1, 2011, 00:00
  • «
  • 131
  • 132
  • 133
  • 134
  • 135 (current)
  • 136
  • 137
  • 138
  • 139
  • 140
  • »